-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-508112-35-00
4
2025-04-15
ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-504550-35-00
5
2025-04-03
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2023-505773-32-00
10
2025-03-25
Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
-
2024-516219-25-00
5
2025-03-25
psoriatic arthritis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-505311-20-01
5
2025-03-21
Metastatic Non-Small Cell Lung Cancer
-
2024-516288-10-00
9
2025-03-21
Liver Cirrhosis
-
2023-508845-41-00
5
2025-03-11
Active juvenile idiopathic arthritis subtypes enthesitis-related arthr
-
2024-515034-33-00
9
2025-03-05
Mantle Cell Lymphoma
-
2024-517262-41-00
5
2025-02-28
Juvenile Psoriatic Arthritis (JPsA)
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-514333-37-00
4
2025-02-25
Advanced Metastatic Ocular/Uveal Melanoma
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2023-509748-89-00
7
2025-02-19
Facioscapulohumeral muscular dystrophy (FSHD)
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2023-509806-31-00
4
2025-02-11
Non-Small Cell Lung Cancer
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-512901-22-00
5
2025-02-10
Acute Heart Failure
-
2024-513128-40-00
4
2025-02-06
Multifocal Motor Neuropathy